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During physical exercise or stress, the sympathetic system stimulates cardiac contractility via β-adrenergic receptor (β-AR) 
activation, resulting in protein kinase A (PKA)–mediated phosphorylation of the cardiac ryanodine receptor RyR2. PKA-
dependent “hyperphosphorylation” of the RyR2 channel has been proposed as a major impairment that contributes to 
progression of heart failure. However, the sites of PKA phosphorylation and their phosphorylation status in cardiac diseases 
are not well defined. Among the known RyR2 phosphorylation sites, serine 2030 (S2030) remains highly controversial as a 
site of functional impact. We examined the contribution of RyR2-S2030 to Ca2+ signaling and excitation–contraction coupling 
(ECC) in a transgenic mouse with an ablated RyR2-S2030 phosphorylation site (RyR2-S2030A+/+). We assessed ECC gain by 
using whole-cell patch–clamp recordings and confocal Ca2+ imaging during β-ARs stimulation with isoproterenol (Iso) and 
consistent SR Ca2+ loading and L-type Ca2+ current (ICa) triggering. Under these conditions, ECC gain is diminished in mutant 
compared with WT cardiomyocytes. Resting Ca2+ spark frequency (CaSpF) with Iso is also reduced by mutation of S2030. In 
permeabilized cells, when SR Ca2+ pump activity is kept constant (using 2D12 antibody against phospholamban), cAMP does 
not change CaSpF in S2030A+/+ myocytes. Using Ca2+ spark recovery analysis, we found that mutant RyR Ca2+ sensitivity is 
not enhanced by Iso application, contrary to WT RyRs. Furthermore, ablation of RyR2-S2030 prevents acceleration of Ca2+ 
waves and increases latency to the first spontaneous Ca2+ release after a train of stimulations during Iso treatment. Together, 
these results suggest that phosphorylation at S2030 may represent an important step in the modulation of RyR2 activity 
during β-adrenergic stimulation and a potential target for the development of new antiarrhythmic drugs.
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Introduction
In heart muscle cells, Ca2+ release from the SR via cardiac ry-
anodine receptor type 2 (RyR2) channels is a cornerstone of 
excitation–contraction coupling (ECC). During each heartbeat, 
a transient SR Ca2+ release amplifies Ca2+ influx via L-type Ca2+ 
channels (LTCCs) by means of the CICR mechanism. RyR2s are 
thought to be involved, not only in the regulation of cardiac 
Ca2+ signaling but also in the malfunctioning of this mechanism 
during several cardiac diseases (e.g., via posttranslational RyR2 
modifications or RyR2 mutations). Besides this triggered and 
precisely coordinated Ca2+ release, RyR2s can open accidentally 
during diastole, giving rise to spontaneous Ca2+ sparks or even 
Ca2+ waves, which constitute an SR Ca2+ leak and are thought to 
be proarrhythmic via generation of diastolic delayed afterdepo-
larizations (DADs).
RyR phosphorylation has been recognized as a modulator 
of RyR function during both systole and diastole. Furthermore, 
RyR2 (“hyper”)-phosphorylation after chronic β-adrenergic re-
ceptor (β-AR) stimulation has been implicated in Ca2+ signaling 
disturbances during heart failure (HF; Marx et al., 2000). RyR2 
phosphorylation may also acutely precipitate stress-induced 
arrhythmias (e.g., catecholaminergic polymorphic ventricular 
tachycardias [CPVTs] in patients harboring RyR2 mutations; 
George et al., 2007).
Within the large tetrameric RyR2 macromolecular complex, 
several phosphorylation sites have been identified, often in stra-
tegic proximity to protein kinases and phosphatases scaffolded 
to the RyR. Both coordinate the extent of phosphorylation for 
specific sites, such as during β-AR activation. Among the identi-
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fied phosphorylation sites, three have been found to change RyR2 
activity, and their impact on cardiac function has been partly 
characterized over the past years: serine 2808 (S2808), S2814, 
and S2030 (Witcher et al., 1991; Wehrens et al., 2004; Xiao et al., 
2005). However, the precise functional consequences of their 
phosphorylation are controversial (Bers, 2012; Valdivia, 2012). To 
examine the role of RyR2 phosphorylation of these specific sites 
from the molecular level to the complexity of an intact organism, 
transgenic mice have been created for the S2808 and S2814 sites, 
which are also referred to as the “phosphorylation hotspot.” Ei-
ther the modified RyR2 channels in these mice lack the phosphor-
ylation site (S2808A, S2814A) or the animals are engineered to 
mimic a constitutively phosphorylated site (S2808D and S2814D).
S2808A mice appeared to exhibit a minor phenotype on the 
level of cellular Ca2+ signaling, even during β-AR stimulation 
(Ullrich et al., 2012). These transgenic mice show partial HF 
cardioprotection after myocardial infarction in some studies 
(Wehrens et al., 2006), but not in others, (Zhang et al., 2012), 
possibly depending on the particular infarct model or other 
experimental differences (for review, see Niggli et al., 2013). 
Myocytes isolated from constitutively phosphorylated S2808D 
mice show elevated Ca2+ spark frequencies and reduced SR–Ca2+ 
content, and the hearts develop an age-dependent hypertrophy 
(Shan et al., 2010). Mice harboring mutations of the RyR2-S2814 
site generally have a more pronounced phenotype. The RyR2-
S2814A mutation presents with slowed progression of HF and 
cardiac remodeling after transverse aortic constriction, and the 
isolated cells exhibited fewer Ca2+ waves and a reduced SR Ca2+ 
leak (Respress et al., 2012). Mice with the S2814D mutation have a 
propensity for ventricular arrhythmias and sudden cardiac death 
when stressed (van Oort et al., 2010).
Regarding the more recently discovered S2030 phosphoryla-
tion site, the information available in the literature is still rather 
scarce. This site was found to be phosphorylated by PKA, but to 
an appreciable extent only after β-AR stimulation (Xiao et al., 
2005). For functional studies, phosphomutant RyR2-S2030A and 
S2030D channels have been expressed in HEK293 cells (Xiao et 
al., 2007). In lipid bilayer experiments, reconstituted S2030D 
channels were found to have a much higher sensitivity for the 
SR luminal Ca2+ concentration than the S2030A variant, whereas 
the S2030A modification showed a blunted response to PKA.
To define the implications of the RyR2-S2030 site in the na-
tive cellular environment of the channel, we engineered a RyR2-
S2030A+/+ knock-in mouse in which the RyR2 channel cannot 
be phosphorylated at the S2030 residue, in analogy to the previ-
ously established transgenic models for other RyR2 phosphoryla-
tion sites. Using cardiomyocytes isolated from these animals, we 
examined ECC and Ca2+ signaling by combining laser-scanning 
confocal Ca2+ imaging with a variety of experimental approaches. 
Our data suggest that the S2030 site contributes considerably to 
the molecular and cellular response during β-AR stimulation.
Materials and methods
RyR2-S2030A+/+ mouse line
All mice were handled according to the Guide for the Care and 
Handling of Laboratory Animals published by the National In-
stitutes of Health and National Research Council of the National 
Academy of Sciences and with permission of the State Veterinary 
Administration and according to Swiss Federal Animal protec-
tion law (permit BE 108/15). The murine RyR2 gene sequence 
was derived from 129Sv CITB BAC library (Thermo Fisher Sci-
entific). The S2030A mutation (serine-to-alanine substitution) 
and NEO selection cassette were introduced into a plasmid by 
recombination engineering. The mutation was inserted to gen-
erate a new specific recognition sequence for the SalI restriction 
enzyme. The vector was electroporated into mouse R1 embry-
onic stem cells, and the clones were selected for growth on G418. 
480 NEO clones were expanded and genomic DNA isolated from 
each clone. Southern blot and DNA sequence analysis identified 
the clones that had integrated the S2030A substitution and the 
NEO cassette by homologous recombination. These clones were 
injected into C57BL/6 blastocysts. Chimeric founders were back-
crossed to C57BL/6 mice twice, and the agouti pups carrying the 
RyR2-S2030A+/+ mutation were identified by Southern blot and 
PCR. Heterozygous mice (RyR2-S2030A+/−) were then crossed 
with 129Sv WT mice and maintained in this genetic background 
for multiple generations.
The genotyping was performed on mouse tail genomic DNA 
with primers that detect a sequence of 325 bp (forward primer: 
5′-CAG TTT TTA ATG AGA TG-3′; reverse primer: 5′-AAT AAC CAT 
GAA CTC TGT-3′). The detection of the homozygous (S2030A+/+) 
or the WT (S2030A−/−) alleles was possible after digestion of the 
PCR amplified sequence with SalI.
The ratio of heart weight (HW) to body weight (BW) was mea-
sured and used as an index of hypertrophy. Specifically, the BW 
of RyR2-S2030A+/+ and age-matched WT mice (∼5 mo old), were 
measured before the heparin injection. Hearts trimmed of extra-
cardiac tissue were weighed immediately after surgical removal 
and prior cannulation. Fig. S1 shows that S2030A+/+ mice had a 
significantly higher HW/BW ratio.
Transthoracic echocardiography was performed with a Vevo 
2100 system with a 22–55 MHz transducer (MS550D; Visual 
Sonics), as described previously (Benkusky et al., 2007). In brief, 
mice (n = 7 for both WT and S2030A+/+) were anesthetized by 5% 
isoflurane inhalation and maintained in the anesthetized state 
by 1.5–2% isoflurane. Two-dimensionally guided B-mode images 
of the left ventricle (LV) were acquired at the tip of the papillary 
muscles. LV volume was measured during systole and diastole, 
stroke volume, and ejection fraction. The fractional shortening 
was calculated by the formula [(LV diameter diastole – LV diam-
eter systole)/LV diameter diastole] × 100.
Isolation of ventricular cardiomyocytes
To reduce variability between animals, the study was performed 
only in male mice. Ventricular myocytes were isolated from 
RyR2-S2030A+/+ male mice and WT littermates according to an 
established protocol (Louch et al., 2011). Briefly, 4- to 8-mo-old 
mice were euthanized by cervical dislocation and the hearts were 
excised, cannulated and retrogradely perfused on a custom made 
Langendorff system. 100 µl of heparin (2,000 units/ml) was in-
jected 10 min before the heart removal to prevent blood coag-
ulation. To isolate the cardiomyocytes, hearts were perfused at 
37°C for 15 min with a Ca2+-free solution composed of (in mmol/
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liter) 140 NaCl, 5.4 KCl, 1.1 MgCl2, 10 HEP ES, 1 NaH2PO4, and 10 
glucose (pH 7.4, adjusted with NaOH). Cells were enzymatically 
dissociated using a cocktail of collagenase type II (160 U/ml, 
Worthington) and protease type XIV (0.21 U/ml; Sigma). After 
isolation, ventricular myocytes were kept at room temperature 
in a solution containing 250 µmol/liter Ca2+ and used within 6 h.
Experimental solutions
During the experiments, cardiomyocytes were perfused with a 
bath solution containing (in mmol/liter) 140 NaCl, 5 HEP ES, 1.1 
MgCl2, 5.4 KCl, 10 glucose, and 1.8 CaCl2 (pH 7.4, adjusted with 
NaOH). For the patch-clamp experiments, the cells were perfused 
with a solution containing (in mmol/liter) 140 NaCl, 5 HEP ES, 1.1 
MgCl2, 5.4 KCl, 10 glucose, 0.5 BaCl2, 1 CsCl, and 1.8 CaCl2 (pH 7.4).
A rapid-switch, gravity-driven superfusion device was used to 
change experimental solutions and expose cells to isoproterenol 
(Iso, 100 nmol/liter) for the β-adrenergic pathway stimulation, 
to ryanodine (50 nmol/liter) for repetitive sparks measurements, 
and to caffeine (10 mmol/liter) to assess Ca2+ content of the SR. 
Iso was prepared for every experiment from a 10 mmol/liter 
stock, and a fresh aliquot of ryanodine was used for each experi-
mental day. The patch pipette solution contained (in mmol/liter) 
120 CsAsp, 8 NaCl, 20 TEA-Cl, 5 MgCl2, 4 K2ATP, 5 HEP ES, and 0.1 
K5-fluo-3 (pH 7.2, adjusted with CsOH).
Myocytes were permeabilized by exposure to β-escin (0.005%) 
for 1 min. The solution used to permeabilize the cells was com-
posed of (in mmol/liter) 100 K-Asp, 20 KCl, 3.7 MgCl2, 0.5 EGTA, 
10 HEP ES, and 0.005% β-escin (pH 7.2). Permeabilized ventric-
ular myocytes were then resuspended in an escin-free solution 
adjusted for Ca2+ spark and Ca2+ wave detection. For Ca2+ spark 
measurements, the solution containing fluo-3 pentapotassium 
salt (50 µmol/liter) was composed of (in mmol/liter) 120 K-Asp, 
3 K2ATP, 0.5 EGTA, 10 HEP ES, and 10 phosphocreatine and 5 U/ml 
creatine phosphokinase, 3 MgCl2, 50 nmol/liter (free) Ca2+, and 
8% wt/vol dextran (to prevent osmotic swelling). For the mea-
surement of Ca2+ waves, the free [Ca2+] was fixed to 0.6 µmol/
liter, to generate a high frequency of Ca2+ release events. Free 
Ca2+ concentrations were measured and adjusted with a Nano-
Drop ND-3300 fluorospectrometer (Thermo Fisher Scientific) 
and Indo-1 pentapotassium salt as a ratiometric Ca2+ indicator (10 
µmol/liter; Biotium). Where indicated, permeabilized myocytes 
were treated with cyclic adenosine monophosphate (cAMP; 5 
µmol/liter) for 5–10 min and with the antibody-binding fragment 
(Fab; 100 µg/ml) of the monoclonal phospholamban (PLB) anti-
body 2D12 (Thermo Fisher Scientific) for 15 min. Unless other-
wise indicated, chemicals were purchased from MilliporeSigma. 
Experiments were performed at room temperature (21°C).
Generation of the 2D12 Fab
To facilitate its penetration into and its distribution inside per-
meabilized myocytes, the 2D12 PLB antibody (1 mg/ml) was frag-
mented by using a commercial kit (Fab Preparation Kit, no. 4468; 
Thermo Fisher Scientific; Chan et al., 2015). In brief, the kit uses 
papain immobilized on agarose resin to digest the antibody, pro-
ducing ∼50 kD Fab and crystallizable fragments. After digestion, 
the Fab was purified from undigested IgG and Fc. Sodium azide 
was present in the 2D12 antibody storage solution. Because this 
solution may be toxic to cells, it was dialyzed with a molecular 
weight cutoff (DiaEasy Dialyzer MWCO 12–14 kD; BioVision). To 
assess digestion completion, the digested fragments were run on 
nonreducing SDS-PAGE. Protein concentration was measured by 
absorbance at 280 nm (NanoDrop Spectrophotometer).
Electrophysiological recordings
For electrophysiological measurements, L-type Ca2+ current (ICa) 
was recorded from ventricular myocytes with the patch-clamp 
technique in the whole-cell configuration with an Axopatch 200 
amplifier (Axon Instruments). Pipettes with ∼1.5-µm tip diame-
ter and 1.5–3 MΩ resistance were pulled from borosilicate glass 
micropipettes (no. G150F-3; Warner Instruments) with a DMZ 
puller (Zeitz Instruments). Cells were allowed 4–5 min for dialy-
sis with the pipette solution. Membrane currents were recorded 
by using custom-written software developed by us in LabView 
(National Instruments), and the data were analyzed with Igor-
Pro software (version 6.34A; WaveMetrics). Cells were held at a 
potential of −80 mV, and an initial step at −40 mV was applied 
to inactivate Na+ and T-type Ca2+ currents (Fig. S2 A). Peak ICa 
was subsequently measured at different membrane potentials 
(from −40 to 0 or −25 to 0 mV) at control and after 3 minutes 
of Iso application. The extent of SR Ca2+ loading was controlled 
and kept comparable, despite Iso application, with a train en-
compassing an appropriate number of depolarization steps (10 
for control and 2 in the presence of Iso) of 200-ms duration at 
0.5 Hz (Fig. S2 B). The train of depolarizations was preceded by 
a rapid caffeine exposure to initiate controlled SR Ca2+ loading 
from an empty SR. In further experiments, a different protocol 
was applied to ensure comparable ICa trigger strength, and com-
parable SR Ca2+ load between all groups (WT and S2030A+/+ cells 
in both conditions, control and during Iso stimulation). After the 
same preconditioning protocol shown in Fig. S2 A, various sized 
currents were recorded (Fig. S2 C): from −40 to −25 up to 0 mV 
(+5-mV steps) in the control and from −40 to −35 up to −10 mV 
for Iso. With Iso, an extra recording was performed with a dif-
ferent range of ICa trigger (from −40 to −30 up to −15 mV, with 
+3-mV steps). Between the recorded currents, a matching pair 
was selected for each cell (WT and mutant), with the mean WT 
ICa used as a reference (±15%). A cell was included in the analysis 
when the difference between the ICa in control and Iso was within 
±15%. The cells were finally selected according to their SR Ca2+ 
content (mean WT, ±15%). The cells that did not meet the crite-
ria were excluded.
Confocal Ca2+ imaging and analysis
Ca2+ transients elicited by ICa at different test potentials were re-
corded by using the Ca2+-sensitive fluorescent indicator fluo-3 
pentapotassium salt (Biotium) dialyzed through the recording 
pipette. Changes in intracellular Ca2+ concentration ([Ca2+]i) 
were recorded with a confocal microscope (FluoView 1000, ×60 
water immersion objective; Olympus) in the line-scan mode at 
a rate of ∼500 lines/s. Fluo-3 was exited at 473 nm with a sol-
id-state laser (MLL-FN-473; Changchun New Industries Opto-
electronics Technology Co.), and light emission was acquired at 
a wavelength of >500 nm. Line-scan images were analyzed with 
ImageJ software (National Institutes of Health) and IgorPro cus-
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tom-written macros. Ca2+ sparks were quantified with the ImageJ 
plug-in “SparkMaster” (Picht et al., 2007).
Intact cardiomyocytes were loaded with 5 µmol/liter fluo-3 
acetoxymethyl ester (AM) for 30 min at room temperature. After 
washout, 30 min were allowed for de-esterification. Laminin (10 
µg/ml) was used to coat the coverslips and to minimize motion 
artifacts. To determine Ca2+ wave parameters, we elicited waves 
by elevating [Ca2+]o to 10 mmol/liter, which resulted in SR Ca2+ 
overload and repetitive Ca2+ waves (Ullrich et al., 2012). A 20-s 
line-scan image was recorded before and 3 min after Iso appli-
cation, and waves were analyzed for propagation velocity. After 
digital deskewing of the wavefront, the line profile of the Ca2+ 
wave was further analyzed for amplitude of the Ca2+ release and 
tau decay (τ) of the waves (Fig. S9 A). Spontaneous Ca2+ sparks, 
the Ca2+ wave frequency, and the latency of the first spontaneous 
Ca2+ wave were recorded after a train of electrical field stimula-
tions at 1 Hz for 30 s (0.5-ms pulses at 20–40 V).
Spark recovery analysis
Isolated ventricular myocytes were loaded with fluo-3 AM (as 
described above) and with EGTA-AM (5 µmol/liter for 30 min, 
to suppress intracellular Ca2+ waves). Repetitive Ca2+ sparks 
originating from the same cluster of RyR2s were elicited with a 
very low ryanodine concentration (50 nmol/liter), as previously 
described (Ramay et al., 2011). Please note that, at such concen-
trations, presumably only a few RyRs have bound ryanodine and 
that all other channels within the active couplon remain in their 
native state. Only prolonged exposure to ryanodine will sig-
nificantly increase the appearance of long-lasting Ca2+ release 
events. For this reason, for each cell, the data acquisition was lim-
ited to a few minutes (maximum, 8 min) until long-lasting release 
events started to appear. Active Ca2+ spark sites were identified 
and recorded by confocal microscopy in line-scan mode in con-
trol conditions and in the presence of 100 nmol/liter Iso. To reach 
steady-state, Iso was applied 3 min before recording. Analysis of 
repetitive Ca2+ sparks was performed with a custom program 
written in MatLab (MathWorks). The criteria of event selection 
were used as previously described (Ramay et al., 2011). In brief, 
myocytes with Ca2+ spark frequencies higher than 15 sparks/100 
µm/s or cells with long-lasting sparks (>200 ms) were excluded 
from analysis. In addition, clusters with 2 subpopulations of 
events (in terms of amplitudes of releases) were excluded from 
the analysis, because they could reflect the overlap of two closely 
spaced clusters of RyR2. All spark-to-spark delays were included 
in the histograms. Amplitude ratios where the initial spark in the 
pair occurred within 200 ms of a previous event were excluded 
to ensure that the first spark in the pair occurred with a fully 
Ca2+-loaded SR. Spark amplitude ratios were fitted with a single 
exponential curve.
Western blot analysis
Freshly isolated cardiomyocytes were treated with Iso at 100 
nmol/liter, in experimental conditions similar to those used for 
the Ca2+ measurements. For a few experiments, a high dose of 
Iso (1 µmol/liter) was combined with the phosphatase inhibitors 
okadaic acid (OA; 10 µmol/liter, CAS no. 155716–06-6; Alomone 
Laboratories) to obtain maximal phosphorylation levels. For the 
control, an equal number of cells was treated with the vehicle. 
After treatment, the cells were lysed with the NP-40 Lysis Buf-
fer kit (ref. FNN0021; Thermo Fisher Scientific) composed of 
(in mmol/liter) 150 NaCl, 1% NP-40, and 50 Tris Base (pH 8). 
The buffer was supplemented with anti-proteases (Complete 
Mini, ref. 4693124001; Roche) and anti-phosphatase cocktails 
(PhosSTOP, ref. 4906845001; Roche). Proteins were quanti-
fied with the Pierce BCA protein assay kit (no. 23227; Thermo 
Fisher Scientific). After quantification, 35–50 µg proteins was 
suspended with 4× Laemmli sample buffer freshly supple-
mented with 2-mercaptoethanol (10% vol/vol), and ultrapure 
water was used to adjust the final volume (40 µl). The proteins 
were separated by a 4–20% SDS-PAGE gradient gel (Mini-Pro-
tean TGX Stain-Free Gels, 60 min at 200 V; Bio-Rad) and trans-
ferred to a polyvinyldine difluoride membrane (0.45-µm pore 
size; BioRad) preactivated with pure ethanol (20 V for 16–18 h at 
4°C). The membranes were subsequently blocked for 1 h at room 
temperature in PBS (ref. A 0975.9010; AxonLab) plus 3% BSA. 
Membranes were then incubated for 3 h in PBS-10% Tween with 
antibodies anti-phospho-RyR2-S2808 (1:2,000, A010-30AP, Ba-
drilla), anti-phospho-RyR2-S2814 (1:500, A010-31AP; Badrilla), 
anti-dephospho-RyR2-S2030 (1:1,000), anti-RyR (1:1,000, C3-33, 
Ab2827; Abcam), and anti-glyceraldehyde phosphate dehydro-
genase (GAP DH; 1:100,000, 10R-G109A; Fitzgerald Biosciences). 
After incubation with primary antibodies, the membranes were 
washed three times for 10 min in PBS-T-0.3% BSA. Membranes 
were then incubated with secondary anti-mouse and anti-rab-
bit antibodies conjugated to horseradish peroxidase (1:10,000, 
115–035-146 and 111–035-144; Jackson ImmunoResearch). After 
washing three times for 10 min (PBS-Tween), protein–antibody 
reactions were detected with Western ECL Substrate (Clarity and 
Clarity Max, 1705060 and 1705062; Bio-Rad) and the ChemiDoc 
MP Imaging System (Bio-Rad). For some experiments anti-rab-
bit Alexa Fluor 680 and anti-mouse Alexa Fluor 790 were used 
as secondary antibodies (1:100,000). Densities of protein were 
measured with Image Lab Software (Life Science Research, Bio-
Rad). The level of the phosphorylation was expressed as the ratio 
of RyR phospho-signal for each antibody and the total anti-RyR 
antibody signal, both normalized for the GAP DH signal used as 
the loading control.
Statistical analysis
Box-and-whisker plots and scatterplots were used in the figures 
to show the distribution of the dataset. Each point represents a 
single measurement from an individual cell. The whiskers cover 
the range from 10% to 90%. In the supplemental tables, data are 
expressed as means ± SEM of n measurements. The statistical 
analysis was performed with IgorPro software and IBM SPSS sta-
tistical software. The Shapiro-Wilk test was used to test the nor-
mal distribution. A logarithmic transformation was performed to 
improve the symmetry when the null hypothesis of the normality 
test was rejected. For the analysis, we used the hierarchical sta-
tistical methodologies as previously shown in Sikkel et al. (2017), 
with the number of animals (N) and the number of cells (n), fol-
lowed by least-significant-difference multicomparisons (all per-
formed in SPSS). Data were paired (experiments with one control 
and one or two test recordings per cell) unless otherwise indi-
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cated. The nonparametric Kruskal-Wallis test was used to com-
pare densities in Western blot experiments. Fisher’s exact test 
was used to compare occurrence of Ca2+ waves between different 
groups. A bootstrap approach (Poláková et al., 2015) was used to 
compute 95% confidence intervals (CIs) for the spark-to-spark 
delay medians. P < 0.05 indicated statistically significant results.
Online supplemental material
Fig. S1 shows the comparison between the HW/BW ratios in WT 
and S2030A+/+ mutant animals. Fig. S2 describes the recording 
protocols used for the electrophysiological measurements. Fig. 
S3 shows Western blots in which the anti-dephospho-S2030 Ab 
was tested on S2030A+/+ protein extraction. Fig. S4 highlights the 
effect of Iso stimulation on PLB for WT and both S2030A+/+ and 
S2808A+/+ mutant myocytes. Fig. S5 indicates the consequences 
of cell permeabilization on RyR2 phosphorylation levels. Figs. S6 
and S7 show the effects of combining 2D12 Fab and cAMP on Ca2+ 
wave frequency, on τ decay of the Ca2+ release, and on SR Ca2+ 
content. Fig. S8 shows the spark amplitude restitution used as 
the control of the successful β-adrenergic simulation in both WT 
and S2030A+/+ during Iso treatment. Fig. S9 describes how the 
Ca2+ wave analysis was performed. Table S1 summarizes the car-
diac functional characterization. Table S2 reports the statistical 
summary of the Ca2+ transient amplitude obtained from the ECC 
gain measurements under matched SR Ca2+ load and matched ICa 
density. Table S3 summarizes the Ca2+ sparks parameters.
Results
ECC gain is decreased in S2030A+/+ myocytes after 
β-adrenergic stimulation at matched SR Ca2+ loading 
and matched ICa
The genetic ablation of the RyR2-S2030 site induces a mild struc-
tural remodeling of the heart. Comparing absolute echocardio-
graphic measurements (Table S1), we found a slight but not 
significant increase in the left ventricular diastolic and systolic 
volume and a normal ejection fraction. Further, we found a higher 
HW-to-BW ratio in S2030A+/+ mice (with no differences in BW), 
which may suggest cardiac hypertrophy (Fig. S1). However, the 
S2030A+/+ line displays no overt phenotype. To compare ECC in 
WT and RyR2-S2030A+/+ ventricular myocytes, we examined the 
functional coupling of LTCCs and RyR2. Specifically, we assessed 
the amount of Ca2+ released per unit of Ca2+ entry, defined as ECC 
gain (Ullrich et al., 2012). Applying the voltage–clamp protocols 
shown in Fig. S2, we simultaneously measured ICa and the trig-
gered Ca2+ transients in control conditions (Fig. 1 A, black traces) 
and during application of Iso (red traces). Note that in Fig. 1 the 
SR Ca2+ content was experimentally standardized between con-
trol and Iso in all cells to minimize the influence of RyR2 modu-
lation by SR luminal Ca2+ (Fig. S2 B; Ogrodnik and Niggli, 2010). 
The density of the currents and the amplitude of the Ca2+ tran-
sients were larger in mutant cardiomyocytes (Table 1). SR Ca2+ 
content was also significantly higher in mutant cells. Because of 
the different SR Ca2+ load between WT and S2030A+/+ cells, the 
ECC gain was normalized to the amplitude of the caffeine-depen-
dent Ca2+ transient. The ECC gain in the mutant myocytes was 
not different at low-triggering ICa (−25-mV step) compared with 
WT (Fig. 1 B), but it was significantly lower at the peak of the ICa 
(0 mV; Fig. 1 C). It has already been reported that β-adrenergic 
stimulation increases the current amplitude more than the Ca2+ 
transient (Bers, 2002). This finding, together with the experi-
mentally matched SR Ca2+ load, explains the decrease in ECC gain 
during Iso stimulation for both animals (Fig. 1, B and C). Upon 
Iso application, the Ca2+ release is systematically enhanced with 
increasing load and/or increasing trigger (Ginsburg and Bers, 
2004). Because of the differences in the ECC machinery reported, 
we also measured the ECC gain in conditions of matched SR Ca2+ 
load and matched ICa between all the groups (see Materials and 
methods and Fig. S2 for details). In these experimental condi-
tions, a change in the gain more reliably reflects a change in RyR 
activity, because the other parameters are experimentally con-
trolled. In brief, the cells were selected according to their SR Ca2+ 
content, and the ICa trigger was maintained constant between 
groups with a recording protocol with variably sized ICa (see Fig. 
S2 C) and by selecting matching pairs of recordings. As previ-
ously shown (Ginsburg and Bers, 2004), in these experimental 
conditions, the ECC gain in WT myocytes was not significantly 
affected by Iso (Fig. 1 D). However, the ECC gain was decreased in 
S2030A+/+ cells after Iso application, mostly because of a reduced 
Ca2+ release during β-adrenergic stimulation (Table S2). These 
results suggest that ablation of the RyR2-S2030 site affects Ca2+ 
release during Iso stimulation and hint at the functional impor-
tance of S2030 phosphorylation during β-AR activation.
Iso application increases RyR2-S2030 
phosphorylation in WT myocytes
To verify Iso-dependent phosphorylation of the RyR2-S2030 site, 
we performed Western blot experiments. Cell homogenates were 
prepared from freshly isolated myocytes in similar experimen-
tal conditions as for Ca2+ measurements. We first measured the 
RyR2 protein expression level by using an anti-RyR Ab, and we 
found that the mutation decreased RyR expression level by ∼43% 
in S2030A+/+ cells (Fig. 2 A). Then, we assessed the RyR2-S2030 
phosphorylation state in WT myocytes before and after treatment 
with Iso using an Ab against dephospho-RyR2-S2030, which spe-
cifically detects the unphosphorylated state of the RyR2-S2030 
site. We found that Iso application significantly decreased the 
fraction of dephospho-RyR2-S2030/RyR in WT ventricular 
myocytes, consistent with an increase of the S2030 phosphor-
ylation (Fig. 2 B). In S2030A+/+ protein extractions, the anti-de-
phospho-Ab also revealed a band, but the intensity of this signal 
was substantially lower compared with WT and, importantly, 
did not change upon Iso application (Fig. S3). The reduction of 
the dephosphorylation level generated by Iso treatment in WT 
cells provided evidence of an increase in S2030 phosphorylation 
during our experimental conditions. To obtain the maximal level 
of RyR2-S2030 phosphorylation, we treated cells with a high dose 
of Iso (1 µmol/liter) in combination with the phosphatase inhib-
itor okadaic acid (OA; 10 µmol/liter). Together, high Iso and OA 
further decreased the fraction of dephospho-RyR2-S2030/RyR 
compared with Iso alone (100 nmol/liter; Fig. 2 C). Considering 
this level as the 100% phosphorylation state of the RyR2-S2030, 
the Iso concentration used in our experiments (100 nmol/liter) 
resulted in an ∼55% phosphorylation of the site. Please note that 
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the decreased expression of RyRs observed in S2030A+/+ mice is 
not expected to substantially affect Ca2+ spark properties, un-
less the number of RyRs per couplon becomes very low (Sobie 
et al., 2002).
Ablation of the S2030 site prevents the increase of the CaSpF 
upon β-adrenergic stimulation during rest
To further test the hypothesis that S2030 may represent a mech-
anistically relevant link between β-adrenergic stimulation and 
RyR2 modulation, we explored the consequences of the S2030 
site ablation on the resting spontaneous Ca2+ release. We com-
pared Ca2+ spark frequency (CaSpF) between WT and S2030A+/+ 
myocytes in control and during Iso application (Fig. 3). In view of 
recent studies in several laboratories demonstrating that CaSpF 
increases rapidly in quiescent cells during β-adrenergic stimula-
tion (Gutierrez et al., 2013; Dries et al., 2016), a modified respon-
siveness of the mutant RyR2-S2030A+/+ receptors may result in a 
lower CaSpF in Iso. In intact cells loaded with fluo-3, basal CaSpF 
was similar between WT and S2030A+/+ cardiomyocytes (Fig. 3 B; 
mean CaSpFs are reported in Table S3; for median values, see 
boxplots in the figures). After application of Iso, the frequency of 
sparks became two times higher in WT compared with S2030A+/+ 
cells. As a positive control, we performed the same experiment 
in another mouse model with a mutation at the RyR2-S2808 site, 
the second PKA-dependent phosphorylation site identified on 
RyR2. In Iso, CaSpF was significantly higher in S2808A+/+ car-
diomyocytes than S2030A+/+ cardiomyocytes (Fig. 3 B), confirm-
ing the potentially important role of the S2030 site during the 
β-adrenergic response. Interestingly, Iso treatment did not in-
crease spark amplitudes and the related spark mass in S2030A+/+ 
cells (Table S3). These results confirm the blunted response of 
the S2030A+/+ mutant myocytes to Iso and suggest that S2030 
Figure 1. ECC gain is decreased in S2030A+/+ myocytes after β-adrenergic stimulation and matched SR Ca2+ loading. (A) Depolarization of volt-
age-clamped cells from −40 to −25 mV (left) or to 0 mV (right) in control conditions and during β-adrenergic stimulation with 100 nmol/liter Iso (N = 5, n = 11 
for both WT and S2030A+/+ animals). The figure shows representative line profiles of the Ca2+ transients (ΔF/F0; black traces for control and red for Iso), confocal 
line-scan images, and ICa traces for both WT and S2030A+/+ cells. (B and C) ECC gain was obtained from the ratio of the maximal Ca2+ transient amplitude and 
the peak ICa density (ΔF/F0)/(pA/pF), normalized to the SR Ca2+ content. (D) The ECC gain was obtained in conditions of matched SR Ca2+ load and ICa between 
all cell groups. The gain was minimally influenced by Iso in WT cells. However, the mutation affected the ECC gain ratio in Iso, mostly because of a decreased 
Ca2+ release during β-adrenergic stimulation (see Table S2). Please note that in this experiment, the SR Ca2+ content was experimentally matched between 
control and Iso. *, P < 0.05, Iso versus control; †, P < 0.05, S2030A versus WT. The whiskers cover the range from 10% to 90%.
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site ablation interferes with RyR2 sensitization upon β-adrener-
gic stimulation. Discrepancies in CaSpF between WT and RyR2-
S2030A+/+ animals could not be explained by different SR Ca2+ 
loading (which was similar between groups; Fig. 3 C) or by the 
SER CA pump stimulation (measured as τ decay of the global 
Ca2+ transient), which was not significantly different between 
animals (Fig. S4). Unlike in the previous experiment, the SR Ca2+ 
load was not matched between control and Iso, and SER CA accel-
eration resulted in a slightly increased SR Ca2+ content. Higher 
SR Ca2+ load in turn may partly contribute to the elevated CaSpF 
in Iso in both WT and S2030A+/+ cells. Therefore, we conceived a 
series of experiments in permeabilized cardiomyocytes, with the 
strategy being to remove SER CA stimulation by cAMP (and thus 
changes in intra-SR Ca2+) as a variable.
cAMP increases CaSpF and SR Ca2+ load in WT and 
S2030A+/+ myocytes
Iso can stimulate phosphorylation of RyR2 as well as phosphol-
amban (PLB) and LTCC, thereby increasing Ca2+ release from the 
SR, SR Ca2+ content, and Ca2+ entry. Because of these substantial 
changes in ECC, it was challenging to dissect the precise func-
tional consequences of RyR2 phosphorylation during β-adrener-
gic stimulation. To remove most of these variables and confirm 
a direct modulation of RyR2 in its cellular environment, we in-
vestigated spontaneous Ca2+ release events in permeabilized my-
ocytes. Free [Ca2+] was clamped at 50 nmol/liter, and cAMP was 
used to activate PKA. In these experiments, basal CaSpF was again 
similar between WT and S2030A+/+ cardiomyocytes (Fig. 4 B i), 
suggesting no functional differences in control conditions. Spark 
frequency was increased by cAMP to similar levels in both WT and 
S2030A+/+ myocytes, reaching the peak after 5–7 min (Fig. 4 B i). 
This finding initially seemed to be in disagreement with our 
observations made earlier in intact cells (see Fig. 3). Because it 
has recently been reported that membrane permeabilization by 
itself may provoke a progressive increase in the RyR2 phosphor-
ylation level at the S2808 site (Bovo et al., 2017), we examined 
whether this phenomenon was occurring in our conditions and 
was the reason for the discrepancy. Using a phosphospecific Ab, 
we did not detect differences in the phosphorylation level at the 
S2808 site before and after 20 min of permeabilization (Fig. S5). 
We also observed that the cAMP-dependent increase in CaSpF 
was associated with an elevated SR Ca2+ content in both cell types 
(Fig. 4 B ii). Because RyR2 activity highly depends on the SR lu-
minal [Ca2+], the lack of differences between WT and S2030A+/+ 
myocytes may be partially caused by the elevated SR Ca2+ loading. 
This effect may obscure differences in RyR2 activity between WT 
and S2030A+/+ cells during cAMP stimulation.
cAMP does not increase CaSpF in S2030A+/+ myocytes after 
maximal stimulation of the SER CA pump
To separate the direct consequences of RyR2 phosphorylation 
from the indirect effect via changes in SR Ca2+ content, we pre-
treated the permeabilized myocytes with the PLB monoclonal Ab 
(2D12) that has been shown to bind PLB and accelerate SER CA ac-
tivity in permeabilized cells. To facilitate the penetration of 2D12 
into the cytosol (Chan et al., 2015), we digested the antibody and 
purified only the Fab. 2D12-Fab accelerated the τ decay of global 
Ca2+ signals, indicating a faster SER CA. The addition of cAMP did 
not further accelerate the pump, suggesting maximal stimulation 
by the Fab (Fig. S6). As a result of the elevated SR Ca2+ level, CaSpF 
was already increased in control conditions compared with basal 
frequency (Fig. 4 D). Starting from maximal SER CA stimulation, 
cAMP application further increased CaSpF in WT myocytes, but 
not in S2030A+/+ cells (Fig. 4 D). The SR Ca2+ content was lower 
in these cells after treatment with cAMP (Fig. S7), most likely 
because of the larger RyR2-mediated Ca2+ leak in WT myocytes. 
These observations suggest that, when SER CA activity is kept 
constant (see Fig. S6), the addition of cAMP unmasks an insensi-
tivity of RyR2-S2030A+/+ channel activity toward PKA-dependent 
phosphorylation, similar to and consistent with the observations 
in intact cells shown in Fig. 3. These results confirm a direct mod-
ulation of RyR2 in the cellular environment and lend additional 
support to the notion that the S2030 site plays an important role 
in RyR2 modulation during the β-adrenergic response.
Table 1. Statistical summary of the ICa density and the Ca2+ transient amplitude
ICa density ICa density Transient amplitude Transient amplitude SR Ca2+ content 
−40/−25 mV (pA/pF) −40/0 mV (pA/pF) −40/−25 mV (ΔF/F0) −40/0 mV (ΔF/F0) (ΔF/F0)
WT (N = 5/n = 11)
Control 0.44 ± 0.16 4.83 ± 0.43 0.45 ± 0.09 2.23 ± 0.29 2.84 ± 0.29
Iso 1.98 ± 0.61a 8.73 ± 0.95a 1.09 ± 0.23a 2.47 ± 0.36a 2.96 ± 0.35
S2030A (N = 5/n = 11)
Control 0.89 ± 0.39 6.87 ± 0.43b 1.04 ± 0.13b 2.93 ± 0.16b 4.46 ± 0.25b
Iso 2.93 ± 0.93a 10.82 ± 1.23a 1.01 ±0.14 2.3 ± 0.19 4.51 ± 0.24
ICa and transients were measured in freshly isolated ventricular cardiomyocytes of WT and S2030A+/+ knock-in mice. Peak ICa was recorded at different 
membrane potentials (from −40 to 0 mV or −25 to 0 mV) in control conditions (1.8 mM [Ca2+]o) and during 100 nmol/liter Iso application. The protocol 
shown in Fig. S2 was used to experimentally match the SR Ca2+ content between control and Iso in all cells. At matched SR Ca2+ load, the Ca2+ release 
in S2030A+/+ myocytes did not increase during Iso, suggesting a decreased RyRs sensitivity (see Fig. 1). Data are expressed as means ± SEM of n 
measurements. 
aP < 0.05 versus control.
bP < 0.05 versus WT.
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The S2030 site is involved in Ca2+ spark-to-spark delay 
shortening during β-adrenergic stimulation
The rate of recovery of Ca2+ sparks after termination (i.e., the 
temporal distribution of their refiring probability) can be used as 
a tool to assess the Ca2+ sensitivity of the RyRs in situ. Interven-
tions that are thought to sensitize RyRs (e.g., Iso and caffeine) or 
inhibit the channels (e.g., tetracaine) can actively shorten or pro-
long the spark-to-spark delay time, respectively (Poláková et al., 
2015). According to our previous results, we hypothesized that 
Ca2+ spark recovery time would be shortened to a lesser extent 
by Iso in S2030A+/+ myocytes. To investigate this hypothesis, we 
performed a Ca2+ spark recovery analysis by using the method il-
lustrated in Fig. 5 A (Sobie et al., 2005). In this method, a low dose 
of ryanodine was used to increase the frequency of Ca2+ sparks. 
The ryanodine-bound RyRs act as Ca2+ source and drive the re-
petitive firing of RyR2 clusters (1–10 per cell) for a limited period 
of time (see Fig. 5 A and paragraph "Relation to previous work 
and limitations" of the Discussion; Sobie et al., 2005). Taking 
advantage of this feature of the RyR–ryanodine binding, we per-
fused the isolated myocytes with ryanodine at a concentration of 
50 nmol/liter (see Materials and methods for details). After the 
Figure 2. RyR2-S2030 site phosphorylation level is increased by Iso 
stimulation. (A) Representative blot showing total RyR2 expression levels in 
WT (N = 8) and S2030A+/+ (N = 10) animals. (B) Representative blot showing 
the level of dephosphorylation at RyR2-S2030 site in WT animals (N = 4), 
before (C, control) and after 100 nmol/liter Iso application. The numbers 1 and 
2 identify different animals. The level of the phosphorylation was expressed as 
the ratio of the dephospho-RyR2-S2030 and the total RyR ODs, both normal-
ized for the GAP DH signal. Please note that a low level of dephosphorylation 
corresponds to a high level of phosphorylation. (C) Representative blot show-
ing the maximal level of dephosphorylation at the RyR2-S2030 site in WT ani-
mals (N = 4) obtained with a high dose of Iso (1 µmol/liter) combined with the 
phosphatase inhibitor OA (10 µmol/liter). The dephosphorylation levels were 
normalized to the control (100%). Iso at the concentration used in all experi-
ments (100 nmol/liter) resulted in a decrease in the signal corresponding to an 
increased level of phosphorylation (69 ± 6% compared with the control). The 
combination of high Iso concentration and OA further decreased the signal 
(44.4 ± 4%). The data are expressed as mean ± SEM of all measurements. *, P 
< 0.05 versus control; **, P < 0.05, Iso versus OA + Iso.
Figure 3. S2030 site ablation limits the Iso-dependent increase in 
CaSpF. (A) Confocal line-scan images showing Ca2+ sparks in intact cells in 
control and after 3 min of 100 nmol/liter Iso treatment for WT (N = 4, n = 
12), S2030A+/+ (N = 4, n = 13), and S2808A+/+ (N = 3, n = 10) myocytes. (B) 
The basal CaSpF (number of sparks per 100 µm/s) was similar among the 
animal groups; after application of Iso, the CaSpF in S2030A+/+ myocytes was 
significantly lower compared with WT and S2808A+/+ cells. (C) SR Ca2+ con-
tent was not significantly different between the mouse models. Please note 
that unlike in the patch-clamp experiments, the SR Ca2+ load here was not 
matched between control and Iso. *, P < 0.05 versus control; †, P < 0.05 versus 
WT. The whiskers cover the range from 10% to 90%.
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recordings, we analyzed the spark-to-spark delay for each Ca2+ 
spark pair (Fig. 5) and the recovery time course of the Ca2+ spark 
amplitude (Fig. S8; see Materials and methods for the criteria of 
event selection). Specifically, the median of the spark-to-spark 
delays histogram was adopted as a parameter defining RyR2s Ca2+ 
sensitivity and the spark amplitude recovery time to estimate the 
local refilling of the SR. In control conditions, medians were not 
significantly different between WT and mutant cells (Fig. 5, B i 
and B iii), suggesting no major differences in basal RyR2 sensitiv-
ity. Iso application left shifted the median of the spark-to-spark 
delay histogram (i.e., shortened the interval) in WT myocytes, 
implying an increase in RyRs Ca2+ responsiveness (Fig. 5 B ii). 
As opposed to WT cells, S2030A+/+ cells did not respond to Iso, 
and there was no shift of the median value (Fig. 5 B iv). The re-
covery of the spark amplitude was accelerated by Iso in both WT 
and S2030A+/+ cells, confirming successful β-adrenergic simula-
tion (Fig. S8). These results confirm that phosphorylation at the 
S2030 site may account for the increased RyR2 sensitivity during 
the β-adrenergic response in WT cardiomyocytes.
Ablation of the S2030 site decreases propensity for 
spontaneous whole-cell Ca2+ release
In cardiac myocytes, a Ca2+ wave is a global Ca2+ signal that 
spreads along the cell and is driven by CICR. During each wave, 
an excess of Ca2+ in the cytosol is extruded by the electrogenic 
Na+–Ca2+ exchanger that can generate a DAD, which could trigger 
an action potential in a single cell (Willis et al., 2016). Changes 
in RyR2 function may alter the propensity for spontaneous Ca2+ 
waves (SCaWs) in S2030A+/+ cardiomyocytes. To test this hypoth-
esis, we measured the occurrence of waves and the latency to the 
first SCaW after a train of stimulations, an indicator of arrhyth-
mogenicity at the single-cell level (Fig. 6). In control conditions, 
we observed a similar rate of occurrence of SCaW (percentage of 
cells showing Ca2+ waves) between WT and mutant cells (Fig. 6 C). 
Iso markedly elevated SCaW occurrences in WT myocytes, but we 
found an only moderate response to β-adrenergic stimulation in 
the mutant cells. Similarly, Iso significantly shortened the mean 
latency to the first SCaW in WT myocytes, but not in S2030A+/+ 
myocytes (Fig. 6 B). Thus, ablation of the S2030 site reduced the 
propensity for whole-cell Ca2+ waves in isolated cardiomyocytes.
The RyR2-S2030A+/+ mutation may also affect the spreading 
of Ca2+ waves. Because the speed of Ca2+ wave propagation has 
been linked to RyR’s Ca2+ sensitivity (Ullrich et al., 2012), we com-
pared Ca2+ wave propagation between WT and mutant cardio-
myocytes before and after application of Iso (Fig. 6 D). To evoke 
a high frequency of Ca2+ waves, we elevated the extracellular 
Ca2+ concentration to 10 mmol/liter, which resulted in SR Ca2+ 
overload (for the protocol used, see Fig. S9). In this condition, the 
SR Ca2+ content is closer to its maximal level, and a difference in 
wave speed more directly reflects a change in RyR sensitivity. In 
control conditions, there were no differences in wave speed be-
tween WT and S2030A+/+ myocytes, but after application of Iso, 
only WT cells showed an acceleration of the Ca2+ wave (Fig. 6 D). 
The lack of wave speed acceleration again confirmed the blunted 
response of CICR in S2030A+/+ cells upon β-AR stimulation. The 
frequency of waves was slightly increased by Iso in both cell 
Figure 4. Maximal SER CA stimulation unmasks a limited cAMP-dependent increase in CaSpF. (A) Representative confocal line-scan images showing 
Ca2+ sparks in β-escin permeabilized cells before and after 5 min in 5 µmol/liter cAMP. (B) Basal CaSpF was similar for WT (N = 5, n = 12) and S2030A+/+ (N = 4, 
n = 10; 2.98 ± 0.34 vs. 3.39 ± 0.47 sparks per 100 µm/s, respectively; i). cAMP enhanced SpF in both cell types. SR Ca2+ content was increased after treatment 
with cAMP (ii). (C) Confocal line-scan images showing Ca2+ sparks in myocytes pretreated with 100 µg/ml 2D12-Fab (15 min) before and after cAMP application. 
(D) 2D12-Fab increased basal CaSpF (6.01 ± 0.41 vs. 5.51 ± 0.56 sparks per 100 µm/s, respectively) for WT (N = 6, n = 10) and S2030A+/+cells (N = 4, n = 10); 
cAMP further increased CaSpF only in WT cells. *, P < 0.05 versus control; **, P < 0.05 versus 2D12-Fab; †, P < 0.05 versus WT. The whiskers cover the range 
from 10% to 90%.
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types. However, no significant differences were found between 
WT and S2030A+/+ cells in control conditions (0.15 ± 0.02 and 
0.19 ± 0.02 waves/s for WT and S2030A+/+ cells, respectively) and 
after Iso treatment (0.29 ± 0.02 waves/s for WT cells and 0.37 ± 
0.04 waves/s for S2030A+/+ cells [mean ± SEM]).
RyR2-S2030A+/+ mice show adaptive changes at RyR2-S2808 
and S2814 phosphorylation sites
Using phosphospecific antibodies, we examined whether the 
RyR2 phosphorylation state at S2808 and S2814 could be altered 
as an indirect consequence of the mutation (Fig. 7 A). We observed 
a 1.8-fold increase in the phosphorylation level at RyR2-S2808 
and a twofold increase in phosphorylation at RyR2-S2814 in mu-
tant myocytes (Fig. 7, B and C). Presumably, the ablation of the 
S2030 site caused adaptive changes in RyR2 phosphorylation at 
the other two major phospho-sites. However, treatment with Iso 
elevated RyR2 phosphorylation at S2808 and S2814 in both WT 
and S2030A+/+ cells (Fig. 7, B and C). These results confirmed that 
the basal phosphorylation at these two sites was not saturated in 
S2030A+/+ myocytes and could be further increased by Iso stim-
ulation. Therefore, the adaptive modifications of the other RyR2 
phosphorylation levels cannot underlie the absence of functional 
RyR2s changes in S2030A+/+ myocytes.
Discussion
During episodes of stress or exercise, activation of the β-adren-
ergic pathway enhances Ca2+ entry via LTCC and Ca2+ reuptake 
into SR store by SER CA stimulation. These mechanisms boost the 
beat-to-beat Ca2+ release, eventually leading to a stronger myo-
cardial contraction. Phosphorylation at specific RyR2 sites may 
enhance Ca2+ release during a β-adrenergic response, possibly 
contributing to positive inotropy and/or Ca2+-induced arrhyth-
mias. Recently, the RyR2-S2030 phosphorylation site has been 
identified and proposed as the major PKA target on RyR2 upon 
β-AR stimulation. The information available in the literature on 
S2030 is limited and largely based on in vitro assays. Therefore, 
to explore the functional role of the S2030 site in the native cel-
lular environment, we engineered an RyR2-S2030A+/+ knock-in 
mouse in which the serine can no longer be phosphorylated.
Modulation of RyR2 function during β-adrenergic response
The functional consequences of RyR2s phosphorylation have 
attracted much recent attention. The interest in the topic grew 
when PKA-dependent phosphorylation of RyR2 at S2808 was 
proposed as the major impairment that contributes to HF pro-
gression (Marx et al., 2000). However, S2808 was found to be 
already substantially phosphorylated at rest in several animal 
species (∼50–75%), raising doubts about the reliability of this site 
as an index of the PKA phosphorylation state (Xiao et al., 2005; 
Huke and Bers, 2008; Fischer et al., 2013). In our work, we found 
a decreased propensity for spontaneous Ca2+ release in S2030A+/+ 
cells (Figs. 3 and 6), which suggested an important role for the 
S2030 site in the modulation of RyR2. The blunted response to 
Iso cannot be explained by the higher SR Ca2+ load and larger ICa 
(Fig. 1), which would rather enhance the Ca2+ release propensity. 
Figure 5. Ca2+ spark-to-spark delay shortening is blunted during β-adrenergic stimulation in S2030A+/+ cells. (A) Representative line-scan image in 
control conditions (i). A very low concentration of ryanodine (50 nmol/liter) entrains repetitive sparks after binding to only a single monomeric RyR channel 
subunit in an entire couplon (ii). The spark-to-spark delay and the relative spark amplitudes were measured to investigate Ca2+ spark restitution (iii). (B) His-
tograms of spark-to-spark delays for control WT (328.8 ms, 95% CI, 313.8–348.3 ms; N = 10, n = 36, 937 spark pairs; i), Iso WT (261.8 ms, 95% CI, 254.5–269.4 
ms; N = 11, n = 44, 1,783 spark pairs; ii), control S2030A+/+ (308.3 ms, CI 95%: 291.6–329.2 ms; N = 6, n = 20, 488 spark pairs; iii), and Iso S2030A+/+ cells (299.6 
ms, CI 95%: 286.0–310.9 ms; N = 7, n = 27, 929 spark pairs; iv). Red lines identify the median values.
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Both alterations, as well as the RyR down-regulation (Fig. 2), are 
likely to be adaptive. Nevertheless, using a series of experimen-
tal approaches that minimize the variability of both, triggering 
Ca2+ and SR Ca2+ content (see Figs. 4 and 5), the S2030A+/+ my-
ocytes still exhibited a substantial insensitivity to PKA activa-
tion. The down-regulation of RyR2 could result from a lower 
number of couplons and/or a reduction of the number of RyRs 
per couplon. However, the number of couplons was found to be 
unchanged in S2030A+/+ mice (Asghari et al., 2017). Furthermore, 
the down-regulation does not appear to compromise ECC in basal 
conditions (Fig. 1 B). Regarding a reduced number of channels 
per couplon, it is generally assumed that the expression of RyRs 
per couplon has a significant redundancy and does not limit the 
SR Ca2+ release, unless the number of channels per Ca2+ release 
site becomes very low (Sobie et al., 2002). Further, a small reduc-
tion in RyRs is not expected to affect spark parameters signifi-
cantly (Cannell et al., 2013). Therefore, the decreased expression 
of total RyR presumably did not play a major role in our results.
In this work, we reported a higher baseline phosphorylation at 
the S2808 and S2814 in S2030A+/+ animals, which most likely re-
flects adaptive modifications as a consequence of S2030 removal. 
As part of a compensatory change, the higher phosphorylation 
at these two sites may overall enhance the baseline Ca2+ release 
activity in the mutant cells. However, we did not detect major dif-
ferences between WT and S2030A+/+ cells in control conditions in 
terms of amount and kinetic of the spontaneous Ca2+ release (see 
Figs. 3, 4, and 6). Moreover, S2808 and S2814 phosphorylation lev-
els were increased by Iso in S2030A+/+ cells. These observations 
are consistent with the hypothesis that the S2030 site plays a role 
in the modulation of RyR2 activity. Our results also point out that 
the tentative RyR2 phosphorylation model developed so far may 
be too simplistic. A “multisite model” of RyR2 phosphorylation 
will most likely better define the RyR modulation (Valdivia, 2012; 
Camors and Valdivia, 2014). RyR2 regulation may depend on the 
combined effect of the kinases on a “phosphorylation hotspot” 
on the protruding side of the receptor (Yuchi et al., 2012) and 
other sites. S2030 is thought to be located in a region that may 
be involved in signal transduction between the transmembrane 
and cytoplasmic domains (Jones et al., 2008). Interestingly, in a 
previous study, we reported that the Ca2+ wave velocity was not 
increased by Iso in S2808A+/+ myocytes, similar to what we now 
found for S2030A+/+ cells (Ullrich et al., 2012). S2808 ablation 
Figure 6. Iso does not modify the latency of the first spontaneous Ca2+ release in S2030A+/+ myocytes. (A) Line-scan images were recorded in the end 
of a train of electrical stimulations at 1 Hz for 30 s. Each cell was recorded in control and after 3 min of 100 nmol/liter Iso treatment. The figure also shows 
line profiles of the triggered Ca2+ transients and the spontaneous Ca2+ releases (ΔF/F0; black traces for the control and red for Iso). The latency was calculated 
considering the last electrical stimulus and the first spontaneous Ca2+ release (arrows). (B) SCaW latency (17.72 ± 3.42 s vs. 8.08 ± 1.16 s), respectively, for 
control and after Iso stimulation for WT (18.04 ± 1.95 s for control vs. 14.27 ± 2.51 s for Iso in S2030A+/+). Latency values were not paired, because not all cells 
displayed SCaW. (C) Occurrence of spontaneous release (percentage of cells that show at least one Ca2+ wave; N = 4, n = 16 for WT; N = 4, n = 15 for S2030A+/+). 
(D) Comparison of wave speed (WT: N = 4, n = 11; 78.42 ± 5.05 µm/s [control] vs. 99.31 ± 4.03 µm/s [Iso]); S2030A+/+: N = 4, n = 15; 83.49 ± 5.56 µm/s [control] 
vs. 85.40 ± 4.64 µm/s [Iso]). In all experiments shown, the SR Ca2+ load was not matched experimentally between control and Iso. *, P < 0.05 versus control; 
†, P < 0.05 versus WT. The whiskers cover the range from 10% to 90%.
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was also observed to prevent the decrease in spark-to-spark de-
lays seen with β-adrenergic stimulation (Poláková et al., 2015). 
Despite the fact that consequences of S2808 phosphorylation are 
subtle and more difficult to detect, in terms of wave speed and 
spark-to-spark delay, the two animal models displayed similar 
behavior, which may suggest a functional link between the RyR2 
regions harboring the mutations. Hence, our study shows that 
the S2030 site plays an important role in the modulation of RyR2 
channels during the β-adrenergic response.
Role of RyR2 in pathophysiology
Excessive β-adrenergic stimulation may result in SR Ca2+ over-
load and increased diastolic SR Ca2+ release. In this study, we 
found that ablation of S2030 site reduces the cellular propensity 
for spontaneous Ca2+ release, suggesting that phosphorylation at 
the S2030 site is involved in changes in RyR2 sensitivity during 
β-adrenergic stimulation. The left shift in the spark-to-spark 
delay histogram, resulting from RyR2 sensitization was minimal 
and far smaller than the leftward shift observed in WT myocytes 
(Fig. 5). The longer refractoriness during β-adrenergic stimula-
tion may desynchronize RyR2 cluster recruitment and partially 
explain the lack of wave speed acceleration we described. These 
data are consistent with previously published results showing 
that PKA does not increase the Po of single RyR2 channels after 
ablation of the S2030 site (Xiao et al., 2007). This resistance to-
ward β-adrenergic stimulation could also manifest itself in the 
probability for Ca2+ wave generation. We found a lower number 
of cells exhibiting spontaneous Ca2+ releases and no reduction of 
the first SCaW latency in S2030A+/+ cells treated with Iso. These 
results show that ablation of the S2030 site decreases the spon-
taneous Ca2+ leak in isolated cells. Diastolic SR Ca2+ leak has been 
associated with HF, and gain- and loss-of-function mutations in 
RyR2 have been linked to CPVT (Marx et al., 2000; Ai et al., 2005; 
Xiao et al., 2005; Priori and Chen, 2011). Even though our work 
does not resolve the controversy over HF and CPVT development, 
the results suggest that preventing RyR2 phosphorylation at the 
S2030 site reduces the probability of initiating diastolic SR Ca2+ 
release and Ca2+ waves in isolated cardiomyocytes.
Potential therapeutic implications
Acute or chronic hyperadrenergic states can lead to the sensi-
tization of the CICR mechanism that becomes unstable. β-AR 
blockers are widely used to reduce the risk for arrhythmias and 
sudden cardiac death. Several studies have been published sug-
gesting that treatment with the Na+ channel inhibitor flecainide 
or with β-blockers (e.g., carvedilol) could stabilize RyR2 function, 
Figure 7. S2030 ablation generates adaptive changes at RyR2-S2808 and S2814 phosphorylation sites in mutant cells. (A) Representative blot showing 
the phosphorylation of RyR2 at the S2808 and S2814 sites in both WT and S2030A+/+ cells in control (C) and during Iso stimulation. (B and C) The level of the 
phosphorylation was expressed as the ratio of the respective phospho- and total RyR ODs, both normalized to the GAP DH signal (N = 8 mice for both WT and 
S2030A+/+ cells were used to compare baseline phosphorylation; between these, N = 4 animals were also assessed after Iso application). These data were tested 
for paired statistical difference. *, P < 0.05 versus control; †, P < 0.05 versus WT. The whiskers cover the range from 10% to 90%.
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possibly via an off-target effect acting as RyR2 open-state block-
ers (Blayney and Lai, 2009; Hilliard et al., 2010). Unfortunately, 
β-AR blockers alone do not perfectly protect all patients in the 
long term. Therefore, additional strategies aimed at preventing 
arrhythmic events are clearly needed. Therapeutic approaches 
directed at stabilization of RyR2 are mechanistically attractive 
strategies. A novel class of RyR-stabilizing drugs, rycals, have been 
shown to improve contractile function in both heart and skele-
tal muscle (Andersson and Marks, 2010). However, many of the 
currently available RyRs stabilizers (e.g., JTV519) have off-target 
actions. Recently, dantrolene, a drug normally used to treat ma-
lignant hyperthermia, has also been shown to suppress arrhyth-
mogenic SR Ca2+ release and DADs (Hartmann et al., 2017). Despite 
the promising outcomes of these studies, more work is needed to 
translate the studies of cells to the intact organism and to poten-
tial clinical applications. In this context of uncertainty, it is critical 
to identify novel compounds that could contribute to RyR2 and 
CICR stabilization. Our study suggests that the RyR2-S2030 site 
could be a new potential target to selectively reduce pathological 
SR Ca2+ leak without altering normal RyR2 and cardiac muscle 
function. The S2030A+/+ transgenic mouse model is the first ex-
perimental system that specifically investigates the role of the 
RyR2-S2030 site in physiological conditions, and it is extremely 
difficult to translate our findings to different cellular systems. 
However, there is the possibility that the RyR2-S2030 site could 
actively participate in the RyRs modulation during the β-adrener-
gic response in human cardiac cells. If this were the case, then we 
speculate that this could represent a target for a specific reduction 
of a pathological SR Ca2+ leak in several conditions, such as CPVT 
and/or HF. More work is certainly required to extend these find-
ings and explore this intriguing perspective.
Relation to previous work and limitations
With the intent to reveal a direct RyR2 modulation, we used the 
Fab of a PLB monoclonal antibody (2D12) to maximally accel-
erate SER CA activity, as previously shown (Chan et al., 2015). 
Starting from a fully stimulated SER CA, cAMP increased CaSpF 
in WT myocytes but not in S2030A+/+ cells. These results con-
firmed that RyR2 can be directly modulated in the cellular en-
vironment and support the idea that the S2030 site plays an 
important role in RyR2 modulation. Our study seems to be at 
odds with results reported previously about the lack of a PKA 
effect on RyR2 in permeabilized cells devoid of PLB (Li et al., 
2002). The discrepancy may come from different experimental 
conditions in terms of acute versus chronic removal of PLB-de-
pendent modulation of SER CA. Moreover, our data do not ex-
clude PKA-independent cellular mechanisms (e.g., Epac) that 
may play a role in RyR2 modulation at S2030 (Pereira et al., 
2012). Nevertheless, we show that the S2030 site is important 
in RyR2 modulation regardless of the actual protein kinase ac-
tivated by cAMP.
We measured the SR Ca2+ content using a similar approach 
in all experiments (assessing the peak of the caffeine-mediated 
transients). However, Figs. 1 and 3 show an apparent discrep-
ancy regarding the difference in the SR Ca2+ load between WT 
and S2030A+/+ cells. The higher baseline SR Ca2+ load in mutant 
cells reported in Fig. 1 is likely to arise from the larger Ca2+ entry 
in this condition (higher ICa; see Tables 1 and S2). The control over 
the Ca2+ entry is potentially less tight in electrical field stimula-
tion (Fig. 3) than in patch-clamp experiments. When the cytoso-
lic Ca2+ concentration was fixed in permeabilized cells (Fig. 4), 
we did not observe differences between WT and S2030A+/+ cells 
in terms of SR Ca2+ content, suggesting that the amount of Ca2+ 
entry may be the reason of the discrepancy.
Recently, it has been reported that membrane permeabili-
zation may progressively increase the RyR2 phosphorylation 
level at the S2808 site (Bovo et al., 2017). In our experimental 
conditions, 20 min of permeabilization did not modify the S2808 
phosphorylation level. The divergence between the studies may 
lie in the permeabilization procedure itself. In our hands, β-escin 
seems to be a gentler agent for membrane permeabilization than 
saponin, and this may limit the loss of accessory proteins or fac-
tors adjusting phosphorylation.
In this study, we also analyzed the rate of recovery of Ca2+ 
sparks after termination, an indicator of the RyR Ca2+ sensitivity 
in situ (Fig. 5). In this approach, a low dose of ryanodine (50 nmol/
liter) was used to increase the frequency of Ca2+ sparks (Sobie 
et al., 2005). Even though this approach provides information 
regarding the sensitivity of the RyRs in different experimental 
conditions (e.g., during caffeine or tetracaine treatment; Ramay 
et al., 2011), the use of ryanodine may have some limitations; it 
is not possible to determine the precise fraction of RyRs in the 
triggered cluster that act as Ca2+ source (“RyR drivers” with ry-
anodine bound), as well as the number of channels without ryan-
odine bound. Moreover, ryanodine may induce long-lasting RyR 
subconductance states and long Ca2+ sparks (Ramay et al., 2011). 
However, the ability of the cluster to refire is directly related to 
the sensitivity of the non–ryanodine-bound channels to react to 
the Ca2+ source. According to this idea, the repetitive nature of 
the recorded events (Fig. 5) suggests that at least some of the RyRs 
in the active site are in their native state. It is also important to 
consider that Ca2+ spark recovery was measured in resting cells, 
where most of the RyRs are in a closed state, and that ryanodine 
preferentially binds to open channels. Moreover, ryanodine was 
applied extracellularly, and its actual concentration may be sub-
stantially lower inside the cell during the first few minutes. All 
this may contribute to the small number of active sites (1–10 per 
cell) and the delayed appearance of the long-lasting events. In any 
case, to account for these potential problems, the data acquisition 
after ryanodine perfusion was limited to a maximum of 8 min or 
to the appearance of the first long-lasting Ca2+ release event (see 
Materials and methods for details and other exclusion criteria).
Conclusions
In summary, we present evidence at the cellular and near-molec-
ular level of an important functional role for the S2030 phosphor-
ylation site in RyR2 modulation during β-adrenergic stimulation. 
We show that ablation decreases the RyR2-mediated diastolic SR 
Ca2+ leak upon β-AR activation. In addition, we provide compel-
ling evidence that interference with S2030 phosphorylation sub-
stantially reduces the cellular susceptibility for whole-cell Ca2+ 
release events, such as Ca2+ waves. Additional studies are needed 
to fully characterize the specific regulation of RyR2 at S2030 by 
PKA and other kinases in normal and diseased heart.
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Figure S1. S2030A+/+ display a higher HW/BW ratio compared with WT animals. HW/BW ratio was measured and used as an index of hypertrophy (see 
Materials and methods for details; WT: N = 11; 31.25 ± 1.07 g [BW]; 262 ± 8 mg [HW]; 8.41 ± 0.21 [HW/BW]; S2030A+/+: N = 8; 32.45 ± 0.86 g [BW]; 311 ± 9 
mg [HW]; 9.61 ± 0.24 [HW/BW]). The data are expressed as mean ± SEM of all measurements. *, P < 0.05 versus WT. The whiskers cover the range 
from 10% to 90%.
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Figure S2. Recording protocols. (A) Myocytes were held at a potential of −80 mV, and an initial step to −40 mV was applied to inactivate Na+ and T-type 
Ca2+ currents. For each cell, peak Ca2+ current was then measured at two membrane potentials (from −40 to −25 mV and −40 to 0 mV) in control and during 
subsequent Iso application. The extent of SR Ca2+ loading in a single cell was controlled under whole-cell patch-clamp conditions by using a train with a 
different number of depolarization steps (10 for control and 2 for Iso) of 200-ms duration at 0.5 Hz. (B) The train of depolarizations was preceded by a rapid 
caffeine exposure in order to reset SR Ca2+ content, and the steady-state in control was achieved after 10 depolarization steps. In Iso, after the initial caffeine 
application, the SR was reloaded with one, two, three, and four depolarizations. We estimated the SR Ca2+ content from the peak amplitude of the caf-
feine-induced transient (ΔF/F0), and we compared control steady state and Iso at an increasing number of stimulations. The amplitude after two depolariza-
tions in Iso was the closest value to control, and it was used to match the control SR Ca2+ content. A cell was considered for analysis when the difference 
between control and Iso SR Ca2+ load was within ±15% (>75% of the patched myocytes). The cells that did not meet the criteria were excluded. (C) To compare 
the ECC gain in myocytes with similar SR Ca2+ load and similar ICa, additional recordings were performed for both WT and S2030A+/+ animals. Starting from 
the same loading protocol shown in A, the cells were selected according to their SR Ca2+ content (mean WT ±15%). For these measurements, the ICa trigger 
was also maintained constant between groups using a recording protocol with variously sized ICa. After the conditioning step, six currents (#) were recorded, 
from −40 to −25 mV up to 0 mV (+5-mV steps) in control and from −40 to −35 mV up to −10 mV for Iso. In Iso, an extra recording was performed with a dif-
ferent range of ICa trigger (from −40 to −30 mV up to −15 mV, with +3-mV steps). Between the recorded currents, a matching pair was selected per each cell 
(WT and mutant) considering the mean WT ICa (±15%). A cell was considered for analysis when the difference between the ICa in control and Iso was within 
±15%. The cells that did not meet the criteria were excluded.
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Figure S3. Iso treatment does not change the dephospho-RyR2-S2030/RyR fraction in RyR2-S2030A+/+ cells. (A) Representative Western blot show-
ing the signal generated by the dephospho-RyR2-S2030 Ab in myocytes isolated from S2030A+/+ animals (N = 4) before (C, control) and after application of 
100 nmol/liter Iso. The numbers 1 and 2 identify different animals. Numbers on the right (250 and 35 kDa) refer to the protein ladder. (B) The dephos-
pho-RyR2-S2030/RyR ratio was significantly lower compared with WT. The dashed blue line represents the median of the WT dephospho-RyR2-S2030/RyR 
fraction reported in Fig. 2. In contrast to WT, the signal was not modified by Iso confirming, indirectly, the ablation of the phosphorylation site. The level of 
the phosphorylation was expressed as ratio of the dephospho-RyR2-S2030 and the anti-RyR Ab OD, both normalized to the GAP DH signal. There are two 
possible reasons for the low signal detected by the dephospho-Ab in S2030A+/+ cells: (1) there is less RyR2 expression in S2030A+/+ cells, and (2) the dephos-
pho-Ab (designed to recognize the dephospho-S2030 site in WT) weakly binds the epitope with the alanine substitution (S2030A+/+), which suggests spec-
ificity of the dephospho-Ab for the S2030 site. (C) Blot showing comparison between WT and S2030A+/+ cells. †, P < 0.05 S2030A+/+ versus WT. The whiskers 
cover the range from 10% to 90%.
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Figure S4. Acceleration of the time course of the Ca2+ transient decay by Iso. The cells were electrically stimulated at 1 Hz for 30 s. (A) Representative 
line profiles of the Ca2+ transients as relative changes in cytosolic Ca2+ concentrations (ΔF/F0; black traces for the control and red for Iso) and the correspond-
ing confocal line-scan images for WT, S2030A+/+, and S2808A+/+ fluo-3 AM–loaded myocytes. (B) τ decay of Ca2+ transients before and after Iso application 
for WT (N = 4, n = 12), S2030A+/+ (N = 4, n = 13), and S2808A+/+ (N = 3, n = 10) myocytes. The amplitude of the Ca2+ transients in control and Iso were com-
parable between the animals (Bers and Berlin, 1995). *, P < 0.05 versus control. The whiskers cover the range from 10% to 90%.
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Figure S5. β-escin permeabilization does not change phosphorylation at the RyR2-S2808 site. (A) Western blot showing the level of RyR2-S2808 site 
phosphorylation before (intact cells [Int]) and after (permeabilized cells [P]) 20 min from the cells’ permeabilization with β-escin. In the gel, samples from 
four different WT animals were run simultaneously. The 250 (kDa) label indicates the molecular weight of the protein ladder. (B) The level of phosphorylation 
was expressed as ratio of the anti-phospho-RyR2-S2808 and the total-RyR signals (OD). *, P < 0.05 versus intact cells. The whiskers cover the range 
from 10% to 90%.
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Figure S6. cAMP does not further accelerate SER CA activity in 2D12-Fab–treated cells. (A) Representative line scans and line profiles recorded in 
permeabilized cells before and after treatment with 100 µg/ml 2D12-Fab (15 min) and 20 µmol/liter cAMP. A monoexponential function was used to fit (red 
lines) the decreasing phase of the Ca2+ waves and measure the τ decay, reflecting SR Ca2+ pump activity. (B) Application of the 2D12-Fab fragment increased 
the frequency of Ca2+ release events. The frequency was further increased after cAMP application (5 min). (C) The τ decay was significantly faster in cells 
treated with the antibody (N = 3, n = 11) than in untreated cells (N = 3, n = 12), indicating a faster activity of the SER CA pump. Further cAMP application (N = 
3, n = 14) did not accelerate the decay, suggesting an already fully activated SER CA. *, P < 0.05 versus control; **, P < 0.05 versus 2D12-Fab. The whiskers 
cover the range from 10% to 90%.
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Figure S7. cAMP decreases SR Ca2+ content in 2D12-Fab–treated WT cells. (A) Representative line-scan images and line profiles of 20 mmol/liter caf-
feine-dependent Ca2+ transients recorded in control and after 2D12-Fab/cAMP combined treatment. (B) SR Ca2+ content is estimated from the amplitude of 
the caffeine-transient (expressed as ΔF/F0). After treatment with the 2D12-Fab fragment, cAMP reduced SR Ca2+ content in WT cells, but not in S2030A+/+ 
cells, mirroring the observation of cAMP-induced Ca2+ sparks exclusively in WT cells (see Fig. 4; N = 3, n = 8 for control and n = 6 for 2D12-Fab + cAMP for 
both animals). *, P < 0.05 versus control. The whiskers cover the range from 10% to 90%.
Figure S8. Spark amplitude restitution. (A and B) Spark amplitude restitution for WT (A) and S2030A+/+ (B) myocytes at control conditions and during 
β-adrenergic stimulation with 100 nmol/liter Iso. Each plot shows the normalized amplitude of the second spark (Aspark2/Aspark1) versus the delay between 
sparks. Spark amplitude ratios were fitted with a single exponential curve (red line; control WT: 62.55 ms, 95% CI, 54.24–70.85 ms, N = 10, n = 35, 749 spark 
pairs; Iso WT: 47.90 ms, 95% CI, 41.65–54.14 ms, N = 11, n = 43, 1,196 spark pairs; control S2030A+/+: 69.93 ms, 95% CI, 57.59–82.26 ms, N = 6, n = 20, 380 
spark pairs; Iso S2030A+/+: 50.13 ms, 95% CI, 41.38–58.87 ms, N = 7, n = 27, 689 spark pairs).
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Figure S9. Ca2+ wave analysis. To evoke the waves, we elevated the extracellular Ca2+ concentration to 10 mmol/liter, which resulted in SR Ca2+ overload. 
(A) Representative line-scan image and the corresponding line profile of a Ca2+ wave induced by high [Ca2+]o. The global line profile did not allow an accurate 
measurement of the time course of the Ca2+ signal. (B) The Ca2+ wavefront has been aligned by digital deskewing, and the related line profile was used to 
measure the τ decay of the Ca2+ signal (representative of SER CA pump activity). (C) Representative line-scan images and line profiles of Ca2+ waves measured 
in WT and S2030A+/+ myocytes. The profiles clearly show that SER CA is stimulated by Iso in both cell types (red traces display a faster decreasing phase). 
Note the differences in the angle of the wavefront (indicated by the blue dashed lines) between WT and S2030A+/+ during Iso treatment.
Table S1. Statistical summary of the echocardiograph measurements
Fractional 
shortening (%)
LV volume 
diastole (µl)
LV volume systole (µl) LV B-mode 
LV ejection 
fraction (µl)
LV B-mode LV 
volume (µl)
LV B-mode stroke 
volume (µl)
WT (N = 7) 31.9 ± 2.0 62.2 ± 4.1 22.3 ± 1.8 57.4 ± 1.4 41.2 ± 2.5 28.2 ± 0.5
S2030A (N = 7) 36.1 ± 4.3 74.4 ± 6 29.0 ± 7 62.9 ± 5.8 42.5 ± 3.5 31.3 ± 2.3
Mice at the age of 3 mo were anesthetized with 5% isoflurane inhalation and maintained in the anesthetized state by 1.5–2% isoflurane. Two-
dimensionally guided B-mode imaging was used to measure the LV volume during systole and diastole, the stroke volume, and the ejection fraction. The 
fractional shortening was also calculated using the formula: [(LV diameter diastole − LV diameter systole)/LV diameter diastole] × 100. The LV diastolic 
and systolic volume and the fractional shortening and ejection fraction were slightly increased in S2030A+/+ animals compared to WT animals, but none of 
the observed differences was statistically significant (all P > 0.05).
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Table S2. Statistical summary of the Ca2+ transient amplitude at matched ICa and SR Ca2+ load
Matched ICa Measured transient 
amplitude 
Matched SR Ca2+ content 
(pA/pF) (ΔF/F0) (ΔF/F0)
WT (N = 3/n = 8)
Control 2.75 ± 0.07 2.27 ± 0.25 2.80 ± 0.11
Iso 2.80 ± 0.12 2.15 ± 0.18 2.88 ± 0.06
S2030A (N = 4/n = 6)
Control 3.09 ± 0.15 2.13 ± 0.29 2.72 ± 0.09
Iso 3.05 ± 0.12 0.90 ± 0.16a,b 2.71 ± 0.14
Using the protocol described in Fig. S2, the SR Ca2+ content (measured as the amplitude of the caffeine-evoked transients) was experimentally matched 
between control and Iso in all cells. We reported a difference in the SR Ca2+ load between WT and mutant myocytes (Fig. 1). To further compare WT and 
S2030A+/+ cells, we assessed the ECC gain in conditions of matched SR Ca2+ load and matched ICa between all the groups (see Fig. S2 for details). In these 
experimental conditions, the Ca2+ release in WT myocytes did not change during Iso. However, the Ca2+ release was decreased in S2030A+/+ after Iso 
application, corroborating the conclusion that the S2030 site may be involved in RyR2 sensitization during the β-adrenergic response. Data are expressed 
as means ± SEM of n measurements. 
aP < 0.05 versus control.
bP < 0.05 versus WT.
Table S3. Statistical summary of the Ca2+ spark parameters
Frequency Amplitude FWHM FDHM Spark mass 
(sparks/100 µm/s) (ΔF/F0) (µm) (ms) (ΔF/F0 × µm3)
WT (N = 4/n = 12)
Control 0.32 ± 0.08 1.10 ± 0.15 2.11 ± 0.12 36.75 ± 2.99 14.51 ± 2.32
Iso 1.95 ± 0.29a 1.59 ± 0.15a 2.18 ± 0.12 36.59 ± 2.83 38.97 ± 13.19a
S2030A (N = 4/n = 13)
Control 0.37 ± 0.07 1.01 ± 0.08 2.09 ± 0.19 36.81 ± 3.49 14.48 ± 4.68
Iso 1.05 ± 0.15a,b 1.08 ± 0.09b 1.97 ± 0.16 38.03 ± 2.52 15.51 ± 3.49b
S2808A (N = 3/n = 10)
Control 0.33 ± 0.07 0.98 ± 0.16 2.14 ± 0.11 39.97 ± 7.46 12.72 ± 1.87
Iso 2.14 ± 0.33a 1.28 ± 0.18a 2.23 ± 0.18 42.43 ± 3.95 34.13 ± 11.36a 
Spontaneous Ca2+ sparks were recorded in intact cells after a train of electrical stimulations at 1 Hz for 30 s (0.5-ms pulses at 20–40 V) and were 
quantified with the ImageJ plug-in SparkMaster. Spark mass was calculated as 1.206 × amplitude × FWHM3. Data are expressed as means ± SEM of n 
measurements. FDHM, full duration at half maximum; FWHM, full width at half maximum.
aP < 0.05 versus control.
bP < 0.05 versus WT.
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